Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL82952 | 1.00 | L3MBTL1 (0.38) | L3MBTL1KDM4ERECQLADRB2ALDH1A1 | |
| Hydrochloric Acid SCHEMBL81154 | 0.98 | L3MBTL1 (0.41) | L3MBTL1KDM4ERECQLADRB2ALDH1A1 | |
| SCHEMBL3695740 | 0.83 | OPRM1 (0.41) | RECQLALDH1A1OPRM1TDP1MEN1 | |
| SCHEMBL438704 | 0.81 | L3MBTL1 (0.40) | L3MBTL1KDM4ERECQLADRB2ALDH1A1 | |
| SCHEMBL13154507 | 0.80 | L3MBTL1 (0.33) | L3MBTL1KDM4ERECQLADRB2ALDH1A1 | |
| SCHEMBL12249026 | 0.80 | OPRM1 (0.39) | KDM4ERECQLALDH1A1OPRM1TDP1 | |
| SCHEMBL12248118 | 0.80 | OPRM1 (0.39) | KDM4ERECQLALDH1A1OPRM1TDP1 | |
| SCHEMBL18412661 | 0.79 | — | — | |
| SCHEMBL11119 | 0.77 | — | — | |
| SCHEMBL83119 | 0.75 | ALDH1A1 (0.36) | ALDH1A1OPRM1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190284208-A1 | N-[(2,4-DIFLUOROPHENYL)METHYL]-6-HYDROXY-3-METHYL-5,7-DIOXO-2,3,5,7,11,11a-HEXAHYDRO[1,3]OXAZOLO[3,2-a]PYRIDO[1,2-d]PYRAZINE-8-CARBOXAMIDE HAVING HIV INTEGRASE INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2019-09-19 | — | — | US | disclosed |
| EP-3284520-B1 | POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY | VIIV HEALTHCARE CO (US) | 2019-06-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190284208-A1 | N-[(2,4-DIFLUOROPHENYL)METHYL]-6-HYDROXY-3-METHYL-5,7-DIOXO-2,3,5,7,11,11a-HEXAHYDRO[1,3]OXAZOLO[3,2-a]PYRIDO[1,2-d]PYRAZINE-8-CARBOXAMIDE HAVING HIV INTEGRASE INHIBITORY ACTIVITY | NR4A1, NR4A2, NR4A3 | L3MBTL1 487/4885KDM4E 720/4885RECQL 2099/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.